{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:16:01Z","timestamp":1791728161089,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ymgmr.2019.100523","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T05:22:55Z","timestamp":1571203375000},"page":"100523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The financial and time burden associated with phenylketonuria treatment in the United States"],"prefix":"10.1016","volume":"21","author":[{"given":"Angela M.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma-Jean E.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgmr.2019.100523_bb0005","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.108.4.972","article-title":"National institutes of health consensus development conference statement: phenylketonuria: screening and management, October 16\u201318, 2000","volume":"108","author":"National Institutes of Health Consensus Development Panel","year":"2001","journal-title":"Pediatrics"},{"issue":"9750","key":"10.1016\/j.ymgmr.2019.100523_bb0010","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymgmr.2019.100523_bb0015","series-title":"Michigan Newborn Screening Program, Annual Report 2015","author":"Kleyn","year":"2017"},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1440-1754.1991.tb00384.x","article-title":"The natural history of untreated phenylketonuria over 20 years","volume":"27","author":"Pitt","year":"1991","journal-title":"J. Paediatr. Child Health"},{"issue":"2","key":"10.1016\/j.ymgmr.2019.100523_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/gim.2013.179","article-title":"Recommendations for the nutrition management of phenylalanine hydroxylase deficiency","volume":"16","author":"Singh","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2019.100523_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgmr.2018.10.002","article-title":"Living with phenylketonuria: lessons from the PKU community","volume":"17","author":"Ford","year":"2018","journal-title":"Molecular genetics and metabolism reports"},{"issue":"6","key":"10.1016\/j.ymgmr.2019.100523_bb0035","doi-asserted-by":"crossref","DOI":"10.1542\/peds.104.6.e68","article-title":"Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors","volume":"104","author":"Seashore","year":"1999","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ymgmr.2019.100523_bb0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10545-010-9073-y","article-title":"The reality of dietary compliance in the management of phenylketonuria","volume":"33","author":"MacDonald","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100523_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ymgme.2009.01.002","article-title":"Optimizing the use of sapropterin (BH4) in the management of phenylketonuria","volume":"96","author":"Blau","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/2042018811402248","article-title":"Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria","volume":"2","author":"Lachmann","year":"2011","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2012.04.004","article-title":"Recommendations for the use of sapropterin in phenylketonuria","volume":"106","author":"Cunningham","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymgme.2014.11.014","article-title":"Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride","volume":"114","author":"Stockler-Ipsiroglu","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100523_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymgme.2017.10.010","article-title":"\u201cMild\u201d hyperphenylalaninemia? A case series of seven treated patients following newborn screening","volume":"122","author":"Viall","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2019.100523_bb0070","author":"Bureau of Labor Statistics"},{"key":"10.1016\/j.ymgmr.2019.100523_bb0075","author":"American Academy of Pediatrics"},{"key":"10.1016\/j.ymgmr.2019.100523_bb0080","author":"Truven Health Analytics"},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2019.100523_bb0085","first-page":"1","article-title":"The costs and benefits of screening for PKU in Wisconsin","volume":"31","author":"Barden","year":"1984","journal-title":"Soc. Biol."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2013.05.003","article-title":"The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands","volume":"109","author":"Eijgelshoven","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10545-016-9995-0","article-title":"Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study","volume":"40","author":"Wang","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2019.100523_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgmr.2016.08.008","article-title":"The personal burden for caregivers of children with phenylketonuria: a cross-sectional study investigating time burden and costs in the UK","volume":"9","author":"MacDonald","year":"2016","journal-title":"Molecular genetics and metabolism reports"},{"issue":"6","key":"10.1016\/j.ymgmr.2019.100523_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2788.2012.01568.x","article-title":"Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet","volume":"57","author":"Guest","year":"2013","journal-title":"J. Intellect. Disabil. Res."},{"key":"10.1016\/j.ymgmr.2019.100523_bb0110","author":"IQVIA Institute for Human Data Science"},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100523_bb0115","first-page":"237","article-title":"Baseline characteristics of PKU patients enrolled in the PKUDOS registry","volume":"102","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100523_bb0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1742-1241.2009.02290.x","article-title":"Are men shortchanged on health? Perspective on health care utilization and health risk behavior in men and women in the United States","volume":"64","author":"Pinkhasov","year":"2010","journal-title":"Int. J. Clin. Pract."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919301612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919301612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:50:42Z","timestamp":1762001442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426919301612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":24,"alternative-id":["S2214426919301612"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100523","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The financial and time burden associated with phenylketonuria treatment in the United States","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100523"}}